Evidence map›Paper›PMID 39340050›Full record

ArticleVaccines2024

Molecular Design of Encapsulin Protein Nanoparticles to Display Rotavirus Antigens for Enhancing Immunogenicity.

Hyun-Gyo Jung, Seonghun Jeong, Min-Ji Kang, Ingi Hong, Young-Shin Park, Eunbyeol Ko, Jae-Ouk Kim, Deog-Young Choi

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hyun-Gyo JungInThera, Inc., Seoul 05836, Republic of Korea.ORCID 0009-0006-2695-3901
Seonghun JeongMolecular Immunology, Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
Min-Ji KangMolecular Immunology, Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
Ingi HongMolecular Immunology, Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
Young-Shin ParkMolecular Immunology, Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.ORCID 0009-0000-7500-3538
Eunbyeol KoMolecular Immunology, Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.
Jae-Ouk KimMolecular Immunology, Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea.ORCID 0000-0002-4556-5553
Deog-Young ChoiInThera, Inc., Seoul 05836, Republic of Korea.

Funding

Ministry of Food and Drug Safety 24202MFDS737RIGHT Foundation RF-TAA-2021-V02
6 · The paper itself

Abstract

Rotavirus considerably threatens global health, particularly for children <5 years. Current, licensed oral attenuated vaccine formulations have limitations including insufficient efficacy in children in low- and middle-income countries, warranting urgent development of novel vaccines with improved efficacy and safety profiles. Herein, we present a novel approach utilizing an encapsulin (ENC) nanoparticle (NP)-based non-replicating rotavirus vaccine. ENC, originating from bacteria, offers a self-assembling scaffold that displays rotavirus VP8* antigens on its surface. To enhance the correct folding and soluble expression of monomeric antigens and their subsequent assembly into NP, we adopted an RNA-interacting domain (RID) of mammalian transfer RNA synthetase as an expression tag fused to the N-terminus of the ENC-VP8* fusion protein. Using the RID-ENC-VP8* tripartite modular design, insertion of linkers of appropriate length and sequence and the universal T cell epitope P2 remarkably improved the production yield and immunogenicity. Cleavage of the RID rendered a homogenous assembly of ENC-P2-VP8* into protein NPs. Immunization with ENC-P2-VP8* induced markedly higher levels of VP8*-specific antibodies and virus neutralization titers in mice than those induced by P2-VP8* without ENC. Altogether, these results highlight the potential of the designed ENC NP-based rotavirus vaccine as an effective strategy against rotavirus disease to address global health challenges.

Indexed as

encapsulinimmunizationnanoparticleneutralizing responserotavirusvaccineVP8

Identifiers

PMID39340050
PMCPMC11435836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.